- Home
- ABUS vs MXCT Comparison
ABUS vs MXCT Comparison
Compare ABUS & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- MXCT
- Stock Information
- Founded
- ABUS N/A
- MXCT 1999
- Country
- ABUS United States
- MXCT United States
- Employees
- ABUS N/A
- MXCT N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ABUS Health Care
- MXCT Health Care
- Exchange
- ABUS Nasdaq
- MXCT Nasdaq
- Market Cap
- ABUS 636.2M
- MXCT 361.8M
- IPO Year
- ABUS N/A
- MXCT 2021
- Fundamental
- Price
- ABUS $3.06
- MXCT $3.47
- Analyst Decision
- ABUS Strong Buy
- MXCT Strong Buy
- Analyst Count
- ABUS 4
- MXCT 2
- Target Price
- ABUS $5.50
- MXCT $9.50
- AVG Volume (30 Days)
- ABUS 997.4K
- MXCT 556.1K
- Earning Date
- ABUS 05-01-2025
- MXCT 03-11-2025
- Dividend Yield
- ABUS N/A
- MXCT N/A
- EPS Growth
- ABUS N/A
- MXCT N/A
- EPS
- ABUS N/A
- MXCT N/A
- Revenue
- ABUS $6,742,000.00
- MXCT $45,599,000.00
- Revenue This Year
- ABUS N/A
- MXCT N/A
- Revenue Next Year
- ABUS N/A
- MXCT $19.79
- P/E Ratio
- ABUS N/A
- MXCT N/A
- Revenue Growth
- ABUS N/A
- MXCT 19.85
- 52 Week Low
- ABUS $2.30
- MXCT $3.17
- 52 Week High
- ABUS $4.72
- MXCT $5.26
- Technical
- Relative Strength Index (RSI)
- ABUS 34.37
- MXCT 34.56
- Support Level
- ABUS $3.32
- MXCT $3.28
- Resistance Level
- ABUS $3.55
- MXCT $3.97
- Average True Range (ATR)
- ABUS 0.17
- MXCT 0.21
- MACD
- ABUS -0.04
- MXCT -0.00
- Stochastic Oscillator
- ABUS 5.88
- MXCT 23.75
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About MXCT MaxCyte Inc.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.